

CASE D0295 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22312-1450.

John A. Lamerdin, Ph.D.  
Type or print name

Signature

12/16/03  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

MUKHERJEE ET AL.

APPLICATION NO: 10/663,002

FILED: SEPTEMBER 16, 2003

FOR: ASSAY FOR PPAR LIGAND DEPENDENT GENE MODULATION

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'John A. Lamerdin', is written over a horizontal line.

John A. Lamerdin, Ph.D.  
Attorney for Applicants  
Reg. No. 44,858


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-3575

Date: 12/16/03

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)


 ATTY. DOCKET NO.  
 D0295 NP  
 APPLICATION NO.  
 10/663,002  
 APPLICANT  
 MUKHERJEE ET AL.  
 FILING DATE  
 SEPTEMBER 16, 2003

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Horoszewicz, et al. "LNCaP Model of Human Prostatic Carcinoma", Cancer Res., Vol. 43, pp. 1809-1818 (1983)
AS	Ryan, et al. "HK-2: An immortalized proximal tubule epithelial cell line from normal adult human kidney", Kidney Int'l., Vol. 45, pp 48-57 (1994)
AT	Jiang, et al. "Modulation of cytosolic phospholipase A <sub>2</sub> by PPAR activators in human preadipocytes", J. Lipid Res., Vol. 42, pp. 716-724 (2001)

EXAMINER


DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)


 ATTY. DOCKET NO.  
D0295 NP  
APPLICATION NO.  
10/663,002  
APPLICANT  
MUKHERJEE ET AL.  
FILING DATE  
SEPTEMBER 16, 2003

Group

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Mukherjee, et al. "Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor $\alpha$ ", J. of Steroid Biochem & Mol. Biol., Vol. 81, pp. 217-225 (2002)
2AB	Kliwer, et al. "Peroxisome Proliferator-Activated Receptors: From Genes to Physiology", Endocrine Society, pp. 239-263 (2001)
2AC	Xu, et al. "Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors", PNAS, Vol. 98, No. 24, pp. 13919-13924 (2001)
2AD	Kliwer, et al. "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors $\alpha$ and $\gamma$ ", Proc. Natl. Acad. of Sci., Vol. 94, pp. 4318-4323 (1997)
2AE	Forman, et al. "Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors $\alpha$ and $\delta$ ", Proc. Natl. Acad. Sci., Vol. 94, pp. 4312-4317 (1997)
2AF	Hsu, et al. "Identification of Peroxisome Proliferator-responsive Human Genes by Elevated Expression of the Peroxisome Proliferator-activated Receptor $\alpha$ in HepG2 Cells", J. of Biolog. Chem., Vol. 276, pp. 27950-27958 (2001)
2AG	Lawrence, et al. "Differential Gene Regulation in Human <i>versus</i> Rodent Hepatocytes by Peroxisome Proliferator-activated Receptor (PPAR) $\alpha$ ", J. of Biol. Chem., Vol. 276, No. 34, pp. 31521-31527 (2001)
2AH	Mukherjee, et al. "Human and Rat Peroxisome Proliferator Activated Receptors (PPARs) Demonstrate Similar Tissue Distribution but Different Responsiveness to PPAR Activators, J. Steroid Biochem. Molec. Biol., Vol. 51, No. 3/4, pp. 157-166 (1994)
2AI	Holness, et al. "Targeted Upregulation of Pyruvate Dehydrogenase Kinase (PDK)-4 in Slow-Twitch Skeletal Muscle Underlies the Stable Modification of the Regulatory Characteristics of PDK Induced by High-Fat Feeding", Diabetes, Vol. 49, pp. 775-781 (2000)
2AJ	Huang, et al. "Regulation of Pyruvate Dehydrogenase Kinase Expression by Peroxisome Proliferator-Activated Receptor- $\alpha$ Ligands, Glucocorticoids, and Insulin", Diabetes, Vol. 51, pp. 276-283 (2002)
2AK	Willson, et al. "The PPARs: From Orphan Receptors to Drug Discovery", J. of Med. Chem., Vol. 43, No. 4, pp. 527-550 (2000)
2AL	Wu, et al. "Mechanism Responsible for Inactivation of Skeletal Muscle Pyruvate Dehydrogenase Complex in Starvation and Diabetes", Diabetes, Vol. 48, pp. 1593-1599 (1999)
2AM	Sugden, et al. "Role of Peroxisome-Activated Receptor- $\alpha$ in the Mechanism Underlying Changes in Renal Pyruvate Dehydrogenase Kinase Isoform 4 Protein Expression in Starvation and after Refeeding", Biochem. and Biophysics, Vol. 395, No. 2, pp. 246-252 (2001)
2AN	Wu, et al. "Adaptive Increase in Pyruvate Dehydrogenase Kinase 4 during Starvation is Mediated by Peroxisome Proliferator-Activated Receptor $\alpha$ ", Biochem and Biophysical Res. Comm., Vol. 287, pp. 391-396 (2001)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.


FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0295 NP  
APPLICATION NO.  
10/663,002  
APPLICANT  
MUKHERJEE ET AL.  
FILING DATE  
SEPTEMBER 16, 2003

Group



## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Wu, et al. "Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart", Biochem. J., Vol. 329, pp. 197-201 (1998)
3AB	Way, et al. "Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor $\gamma$ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues", Endocrinology, Vol. 142, No. 3, pp. 1269-1277 (2001)
3AC	Mukherjee, et al. "Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-activated Receptor (PPAR) Isoforms PPAR $\gamma$ 2 versus PPAR $\gamma$ 1 and Activation with Retinoid X Receptor Agonists and Antagonists", J. of Biol. Chem., Vol. 272, No. 12, pp. 8071-8076
3AD	Brown, et al. "A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPAR $\alpha$ Agonist with Potent Lipid-Lowering Activity", J. Med. Chem., Vol. 42, pp. 3785-3788 (1999)
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.